Spotlight on levetiracetam in epilepsy (Q37936429)

25 August 2017

1 reference

title

Spotlight on levetiracetam in epilepsy (English)

1 reference

Katherine A Lyseng-Williamson

25 August 2017

1 reference

object named as

Katherine A Lyseng-Williamson

series ordinal

1

0 references

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

25

1 reference

25 August 2017

10

1 reference

25 August 2017

901-905

1 reference

https://scigraph.springernature.com/pub.10.2165/11208340-000000000-00000

25 August 2017

0 references

cites work

Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Clinical pharmacokinetics of levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Efficacy and safety of levetiracetam as adjunctive therapy in adult patients with uncontrolled partial epilepsy: the Asia SKATE II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Assessment of a dose-response relationship of levetiracetam.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Dramatic weight loss with levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208340-000000000-00000

Levetiracetam: a review of its use in epilepsy

21 January 2018

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

12 December 2020

Levetiracetam: a long-term follow-up study of efficacy and safety

1 reference

12 December 2020

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

1 reference

12 December 2020

Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.

1 reference

12 December 2020

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures

1 reference

12 December 2020

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

12 December 2020

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

12 December 2020

10.2165/11208340-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21936590

Dimensions Publication ID

25 August 2017

0 references

1 reference

PubMed ID

21936590